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states. Two non-PDL states were used as controls for underlying
market dynamics. Demographics of physicians’ neighborhoods
(poverty and ethnicity) were used to examine the variation in
prescribing based on the characteristics of physicians’ areas of
practice. RESULTS: The post-policy decline in the use of
restricted prescriptions varied considerably, from Florida (−97%)
to Texas (−65%). There was a statistically signiﬁcant positive
association between the magnitude of decline and the share of
impoverished households and the share of the minority popula-
tion in Alabama, Florida and Texas. CONCLUSION: The analy-
sis indicates that there is considerable variation in the impact of
a PDL by state, and in certain states by the degree of poverty or
diversity in the neighborhood. This could imply due to the PDL,
in poorer and more ethnically diverse neighborhoods, fewer
patients receive the restricted medication by prior authorization,
and more patients experience a disruption in their medication
regimen and any resultant unintended consequences. This is an
area worthy of exploration, as the dual eligibles transition into
Medicare part D and may experience changes in formulary.
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OBJECTIVES: To assess racial disparities in initial diagnosis and
follow-up treatment of hypertension. METHODS: This study
identiﬁed newly diagnosed hypertension patients using Medical
Expenditure Panel Survey (MEPS) 1996–2003. Hypertension
was based on self-reported medical conditions with clinical clas-
siﬁcation of “essential hypertension” (CCCODEX = “098”) 
or “hypertension with complications” (CCCODEX = “099”).
Patients were considered newly diagnosed if they reported their
condition to have started during the interview period and had
medical event records on the same dates for hypertension. In
order to assess racial disparities in follow-up treatment, eligible
patients were also required to remain in the survey for at least
6 months immediately after their initial diagnoses. Multivariate
logistic regression method was applied to exam the likelihood of
being initially diagnosed during ofﬁce-based visits and the prob-
ability of having follow-up ofﬁce-based visits using survey pro-
cedures in SAS 9.1 to take into account of complex survey design
and possible confounding factors. RESULTS: The ﬁnal data set
had 572 patients, representing 5.9 million civilian non-institu-
tionalized hypertension patients during years 1996–2003. More
Hispanics (14%, 95% CI = 6–21%) and non-Hispanic Blacks
(15%, 95% CI = 6–24%) were initially diagnosed during non-
ofﬁce-based visits (e.g. ER visits), compared with Whites (8%,
95% CI: 6–11%). After adjusting for confounding factors (age,
gender, family income, education, concurrent medical conditions
and health insurance status), both Hispanics (OR = 0.67, 95%
CI = 0.35–1.27) and non-Hispanic Blacks (OR = 0.56, 95% CI
= 0.25–1.21) had lower odds of being initially diagnosed during
ofﬁce-based visits compared to Whites, although neither esti-
mates were statistically signiﬁcant. Hispanics and Blacks were
also estimated to have lower odds of receiving follow-up ofﬁce-
based visits related to hypertension (Hispanic: OR = 0.83, 95%
CI = 0.45–1.52; Black: OR = 0.59, 95% CI = 0.37–0.94). CON-
CLUSION: Statistically signiﬁcant racial disparities in the likeli-
hood of initial diagnosis of hypertension during ofﬁce-based
visits were not found, although non-Hispanic Blacks were sig-
niﬁcantly less likely to receive follow-up ofﬁce-based visits for
hypertension.
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OBJECTIVES: This analysis examines the effect of mental health
on the health care cost of those suffering from diseases of the
heart. METHODS: We examined Tennessee Medicare reim-
bursement ﬁles for 2002 (inpatient, outpatient, and physicians)
for elderly with diseases of the heart (ICD-9 diagnosis; n =
294,322). The sample included blacks (9.8%), females (57.8%),
and those with a mental health diagnosis (15.16%; n = 44,605).
Analyses of variance and regression (controlling for age, sex, and
race) compared the cost differences between those with and
without mental health diagnosis. RESULTS: The total health
care cost per patient for those with a mental disorder was sig-
niﬁcantly higher than for those without a mental disorder
($35,865 vs. 18,863, p < 0.01; a difference of $17,002 per
patient). After controlling for age, race, and sex, the average cost
per patient reduced by $4,865, that is, from $35,865 to $31,000.
Approximately 8% of the total health cost was for treatment of
mental disorders. Further, among those having both diseases of
the heart and mental disorder, the total health cost was signiﬁ-
cantly higher for males than females ($40,762 vs. $33,865), and
for blacks than whites ($45,855 vs. $34,621). CONCLUSION:
Health care cost is signiﬁcantly higher among heart disease
patients with a mental disorder. A signiﬁcant saving of $4,865
per patient leading to cost saving of 21.7 million could be
attained ($4,865 × 44,605 patients = $21.7 million) through a
special management team that provided treatment parity across
the board.
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OBJECTIVES: To compare the burden of illness among patients
at high and low risk of developing a major cardiovascular event.
METHODS: The retrospective claims analysis included adult
commercial health plan members identiﬁed with a primary diag-
nosis for cardiovascular disease (CVD) such as angina pectoris,
myocardial infarction, hypertension, ischemic heart disease, and
stroke from January 1, 2001–December 31, 2002. The Baseline
period was deﬁned as the 12 month period following the ﬁrst
claim meeting the identiﬁcation criteria within that timeframe.
The Follow-up period was deﬁned as the 24 months following
the Baseline period. Members were categorized into three risk
groups: low risk (LR), high risk (HR), and high risk aged 55 and
over (HR55). Demographic and clinical characteristics, utiliza-
tion, and costs were analyzed for the risk groups. Patients who
died were removed from this analysis and examined separately
due to signiﬁcant differences from the overall study population.
RESULTS: Most patients fell into the low risk group (8% in
HR55, 7% in HR, 85% in LR) based on the study criteria. A
signiﬁcantly greater proportion of patients in the HR55 group
were hospitalized during follow-up (30%) compared to the HR
group (21%) and the LR group (15%) at p < 0.001. Among
HR55 patients, 68% of the hospitalizations were CV-related.
HR55 patients experienced an average of 34 ambulatory visits
in the 24-month Follow-up period, signiﬁcantly greater than HR
patients (28 visits, p < 0.001) and LR patients (24 visits, p <
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0.001). Controlling for covariates, HR55 patients averaged
$22,502 in paid health care services over 2 years compared to
$15,645 for HR patients and $11,423 for LR patients (p <
0.001). CV costs represented about 46% of costs for the HR55
group, 41% for the HR group, and 31% for the LR group.
CONCLUSION: This study demonstrates the high burden of
illness associated with CVD, especially for patients within the
high risk group aged 55 and over.
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OBJECTIVES: To estimate rates of non-adherence for statins 
following implementation of a preferred drug list (PDL).
METHODS: In a retrospective cohort study, a difference-in-
difference-in-difference approach was used to estimate the
impact of a PDL on statin utilization in an Alabama Medicaid
population. The PDL restricted access to certain branded med-
ications and imposed a monthly prescription limit. The use of
restricted drugs was compared with the use of unrestricted drugs
in the months before and after the PDL in North Carolina (where
there were no such restrictions) and Alabama. Pharmacy data
from 2001 to 2005 were used to examine the effect of the
Alabama PDL implemented in 2004. RESULTS: Following the
PDL in Alabama, Medicaid beneﬁciaries treated with statins had
an 82% higher relative odds of becoming non-adherent with
statin therapy compared with North Carolina and with pre-PDL
Alabama [odds ratio (OR) 1.82, 95% CI 1.57, 2.11]. Further-
more, patients taking a restricted statin were more likely to be
non-adherent than unrestricted patients (OR 1.42, 95% CI 1.12,
1.80). In addition, among Medicaid beneﬁciaries taking a
restricted statin, people aged 65 years or older were more likely
to be non-adherent than their younger counterparts after the
PDL (OR 1.33, 95% CI 1.02, 1.73). Fifty-one per cent of
patients in the Alabama sample were non-adherent with statin
therapy after the PDL, compared with 39% before. Non-adher-
ence was 36% in North Carolina in both periods. CONCLU-
SION: The management of heart disease and high cholesterol are
important challenges, especially for low-income patients. Policy
makers should be aware that access restrictions can have adverse
consequences for patient adherence.
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OBJECTIVES: To develop an evidence-based, real world data
driven interactive model to predict LDL reduction and National
Cholesterol Education Program (NCEP) LDL goal attainment in
patients receiving statin monotherapy. METHODS: An interac-
tive model was developed using data from patients receiving
statins between January 1, 2001 and December 1, 2005 from
two large Southeastern US health plans’ administrative claims
with integrated lab results data. Multivariate OLS regression was
used to predict the percent change in LDL associated with dif-
ferent doses of statin monotherapies for various patient charac-
teristics such as age, gender, NCEP risk factors, presence of
coronary heart disease (CHD) /CHD risk equivalents, and base-
line lipid values. Each patient was assigned a NCEP risk clas-
siﬁcation and corresponding LDL goal, and the patient’s
probability of reaching goal was calculated by simulating a dis-
tribution of the expected percent change and its 95%CI obtained
from the regression. RESULTS: A total of 33,706 patients were
used to build the model. The cohort had a mean age of 54(+10)
years and was 51% male. A total of 41% of patients were clas-
siﬁed as low, 22% as moderate, 30% as high, and 7% as very
high risk based on NCEP criteria. LDL reduction associated with
atorvastatin 10–80 mg, rosuvastatin 5–40 mg and simvastatin
10–80 mg ranged from 35–38%, 31–39% and 24–34%, respec-
tively. The multivariate regression indicated that NCEP risk
status and baseline LDL values were signiﬁcantly associated with
higher reduction in LDL (p < 0.05), independent of type and dose
of statin monotherapy. CONCLUSION: Real world, data driven
interactive models may help decision makers identify patients
that are ideal candidates for cost-effective statin prescribing that
results in substantial cost savings while improving health out-
comes. Models such as this will allow clinicians, health plan
administrators and patients to maximize the economic beneﬁt of
marketplace changes such as generic simvastatin availability in
a clinically appropriate fashion.
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OBJECTIVES: The incorporation of computed tomography
angiography (CTA) scanners into cardiology practices to provide
optimal patient care is increasing. However, little is known about
how these scanners are being used in these practice settings;
therefore, the objective of this study was to assess the real world
CTA procedural mix and volume data from a large cardiovas-
cular practice. METHODS: Data for a one year time period fol-
lowing purchase of a CTA scanner were abstracted from a
moderate size practice consisting of ten cardiologists. A descrip-
tive analysis was conducted to determine the CTA procedural
mix and volume for each of the 12 months that the practice has
owned the CTA scanner. The mix and volume were charted over
time and the average daily procedural volume and mix was quan-
tiﬁed. RESULTS: During the ﬁrst month of ownership, the prac-
tice performed a total of 6 chest studies on the CTA scanner.
However, by the second month of ownership, the total volume
of scans increased to 169 (124 chest, 11 coronary artery calcium
screens, 7 head, 10 neck, 7 abdomen, and 10 legs). The volume
of scans remained consistent for months 3 through 12 with an
average monthly volume of 298 procedures (range 186–384).
Assuming an average of 20 operating days/month, the average
daily procedural volume following the ﬁrst month of ownership
was 14 procedures per day, broken out as follows: chest (7, range
5.6–8.6); coronary artery calcium screen (2, range 0.6–5); head
(0.7, range 0.4–1.3), neck (0.8, range 0.5–1.4); abdomen (0.6,
range 0.4–0.9); pelvis (0.04, range 0–0.2); legs (0.4, range
0–0.7); abdomen with run-off (0.5, range 0–0.9). CONCLU-
SION: Following purchase of a CTA scanner, a cardiology prac-
tice may perform only a few procedures during the ﬁrst month
of ownership; however, the procedural volume and mix sub-
stantially increases during the second month and remains con-
sistent thereafter.
